ClinicalTrials.gg
CompletedNCT05610280Updated Feb 10, 2026

A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia

A Phase 3 interventional study of Olezarsen and Placebo in Hypertriglyceridemia, Cardiovascular Diseases and Atherosclerosis, sponsored by Ionis Pharmaceuticals, Inc.. Completed at 168 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Ionis Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2024, 2 years 3 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jul 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,478
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc. — 1 open to participants now, 2 under way, 1 of them phase 3. Hypertriglyceridemia · Ionis Pharmaceuticals, Inc..

Enrollment
Largest of 12
1,478 · median 114
Started
2022
with 3 others
Phase 3
5 of 12
none open now
Registered
10th of 12
by date

Among the 12 studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc., this one has the largest enrollment, is one of 4 that started in 2022, is one of 5 in phase 3, and was the 10th registered.

Hypertriglyceridemia

324 studies on the registry are indexed under Hypertriglyceridemia; 38 are open to participants now.

Browse Hypertriglyceridemia studies →

Open to participants now

1 of the 12 studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc. is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 22 Hypertriglyceridemia studies recruiting now, 9 (41%) set no upper age limit and 12 (55%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc., or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo in participants with hypertriglyceridemia and atherosclerotic cardiovascular disease, or with severe hypertriglyceridemia.

Read the detailed description

This is a Phase 3, multi-center, placebo-controlled study in approximately 1475 participants with hypertriglyceridemia and atherosclerotic cardiovascular disease. The study consists of 3 periods: 1) Screening Period: Week -12 to Week -1 (up to 12 weeks); 2) Treatment Period up to Week 53; and 3) Post-Treatment Follow-up Period: Week 54 to Week 66 (13 weeks). Participants enrolled will receive olezarsen or placebo once every 4 weeks during the 53-week Treatment Period.

The Screening Period was extended with no impact to overall study timelines.

A coronary computed tomographic angiography (CTA) sub study will be performed to assess whether triglyceride lowering through inhibition of apoC-III protein synthesis may reduce coronary plaque progression.

03

Conditions studied

  • Hypertriglyceridemia
  • Cardiovascular Diseases
  • Atherosclerosis

Keywords

  • ISIS 678354
  • Olezarsen
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must fall into 1 of the following groups (a or b):

    a. Hypertriglyceridemia with fasting TG ≥200 mg/dL (2.26 millimoles per liter [mmol/L]) and \<500 mg/dL (5.65 mmol/L) with either

  • Clinical diagnosis of atherosclerotic cardiovascular disease (ASCVD) or
  • At increased risk for ASCVD

    b. Severe hypertriglyceridemia with fasting TG ≥500 mg/dL (5.65 mmol/L)

  • Participants should be on standard of care (SOC) lipid-lowering medications per local guidelines. Lipid-lowering medications should be optimized and stabilized for at least 4 weeks prior to Screening to minimize changes in these medications during the study.

Exclusion criteria

Exclusion Criteria:

  • (HbA1c) ≥ 9.5% at Screening
  • or aspartate aminotransferase > 3.0 ×
  • Total > 1.5 upper limit of normal unless due to Gilbert's syndrome
  • Estimated \< 30 mL/min/1.73 m\^2

NOTE: Other Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,478 participants (actual)

Study arms

  • Experimental
    Olezarsen

    Participants will be randomized to receive multiple doses of olezarsen, once every 4 weeks by subcutaneous (SC) injection up to Week 49.

    Drug: Olezarsen

  • Placebo comparator
    Placebo

    Participants will be randomized to receive olezarsen-matching placebo, once every 4 weeks by SC injection up to Week 49.

    Drug: Placebo

Interventions

  • Olezarsen will be administered by SC injection.

    Also known as: ISIS 678354, AKCEA-APOCIII-LRx

  • DrugPlacebo

    Olezarsen-matching placebo will be administered by SC injection.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline to Week 25 in Fasting Triglycerides (TG) Compared to Placebo

    Time frame: Baseline to Week 25

Secondary outcomes

  1. Percent Change From Baseline to Week 53 in Fasting TG Compared to Placebo

    Time frame: Baseline to Week 53

  2. Proportion of Participants who Achieve Fasting TG <150 Milligrams per Deciliter (mg/dL) at Weeks 25 and 53 Compared to Placebo

    Time frame: Baseline, Weeks 25 and 53

  3. Percent Change From Baseline to Weeks 25 and 53 in Fasting Apolipoprotein C-III (apoC-III) Compared to Placebo

    Time frame: Baseline to Weeks 25 and 53

  4. Percent Change From Baseline to Weeks 25 and 53 in Fasting Very Low-Density Lipoprotein-Cholesterol (VLDL)-C Compared to Placebo

    Time frame: Baseline to Weeks 25 and 53

  5. Percent Change From Baseline to Weeks 25 and 53 in Fasting Remnant Cholesterol Compared to Placebo

    Time frame: Baseline to Weeks 25 and 53

  6. Percent Change From Baseline to Weeks 25 and 53 in Fasting non-High Density Lipoprotein-Cholesterol (HDL)-C Compared to Placebo

    Time frame: Baseline to Weeks 25 and 53

  7. Percent Change From Baseline to Weeks 25 and 53 in Fasting High-Density Lipoprotein-Cholesterol (HDL)-C Compared to Placebo

    Time frame: Baseline to Weeks 25 and 53

  8. Percent Change From Baseline to Weeks 25 and 53 in Fasting Apolipoprotein B (apoB) Compared to Placebo

    Time frame: Baseline to Weeks 25 and 53

  9. Percent Change From Baseline to Weeks 25 and 53 in Fasting Low-Density Lipoprotein-Cholesterol (LDL)-C Compared to Placebo

    Time frame: Baseline to Weeks 25 and 53

07

Study locations

168 sites
  • Alabama Clinical Therapeutics, LLC Alabaster
    Birmingham, Alabama 35235, United States
  • Heart Center Research PC
    Huntsville, Alabama 35801, United States
  • Cardiovascular Research Foundation of Southern California
    Beverly Hills, California 90210, United States
  • Westside Medical Associates of Los Angeles
    Beverly Hills, California 90211, United States
  • Diabetes/Lipid Management & Research Center
    Huntington Beach, California 92648, United States
  • University of California, San Diego (UCSD)
    La Jolla, California 92037, United States
  • Clinical Trials Research
    Lincoln, California 95648, United States
  • Amicis Research
    Northridge, California 91324, United States
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
  • Northern California Research
    Sacramento, California 95821, United States
  • Amicis Research Center
    Santa Clarita, California 91344, United States
  • Metabolic Institute of America
    Tarzana, California 91356, United States
  • Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center
    Torrance, California 90502, United States
  • Amicis Research Center
    Valencia, California 91355, United States
  • Excel Clinical Medical Trials
    Boca Raton, Florida 33434, United States
  • Finlay Medical Research - West Palm
    Greenacres City, Florida 33467, United States
  • Global Research Associates
    Homestead, Florida 33030, United States
  • 3Sync Research
    Lake Worth, Florida 33460, United States
  • Finlay Medical Research
    Miami, Florida 33126, United States
  • Advanced Medical Research Institute (AMRI)
    Miami, Florida 33174, United States
  • De La Cruz Research Center, LL
    Miami, Florida 33184, United States
  • Suncoast Clinical Research, Inc. - New Port Richey
    New Port Richey, Florida 34652, United States
  • Suncoast Clinical Research, Inc. - Palm Harbor
    New Port Richey, Florida 34652, United States
  • Proactive Clinical Research
    Oakland Park, Florida 33309, United States
  • Ocala Cardiovascular Research
    Ocala, Florida 34471, United States
  • Comprehensive Medical & Research Center
    Plantation, Florida 33317, United States
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
  • St. Johns Center for Clinical Research
    Saint Augustine, Florida 32086, United States
  • JSV Clinical Research Study, Inc
    Tampa, Florida 33634, United States
  • Centricity Research
    Columbus, Georgia 31904, United States
  • Atlanta Heart Specialists
    Tucker, Georgia 30084, United States
  • Evanston Premier Healthcare Research LLC
    Evanston, Illinois 60201, United States
  • Clinical Investigation Specialists, Inc
    Gurnee, Illinois 60031, United States
  • Affinity Health
    Park Ridge, Illinois 60068, United States
  • Cardiovascular Research of Northwest Indiana, LLC
    Munster, Indiana 46321, United States
  • Reid Hospital and Health Care Services
    Richmond, Indiana 47374, United States
  • West Broadway Clinic
    Council Bluffs, Iowa 51501, United States
  • Mercy One Iowa Heart Center
    West Des Moines, Iowa 50266, United States
  • University of Kansas Medical Center (KUMC)
    Kansas City, Kansas 66160, United States
  • Norton Cardiovascular Associates
    Louisville, Kentucky 40205, United States
  • Louisville Metabolic and Atherosclerosis Research Center
    Louisville, Kentucky 40213, United States
  • Maryland Cardiovascular Specialists
    Baltimore, Maryland 21229, United States
  • Aa Mrc, Llc
    Flint, Michigan 48504, United States
  • Palm Research Center, Inc.
    Las Vegas, Nevada 49148, United States
  • Clinical Research of South Nevada
    Las Vegas, Nevada 89104, United States
  • Palm Research Center, Inc.
    Las Vegas, Nevada 89148, United States
  • Medical University of South Carolina (MUSC)
    Charleston, North Carolina 29425, United States
  • Moses H. Cone Memorial Hospital
    Greensboro, North Carolina 27401, United States
  • Aultman Hospital Cardiology Clinical Trials
    Canton, Ohio 44710, United States
  • McConnell Heart Health Center
    Columbus, Ohio 43214, United States
  • Summit Research Group, LLC
    Stow, Ohio 44224, United States
  • Central Oklahoma Early Detection Center
    Edmond, Oklahoma 73034, United States
  • Green and Seidner Family Practice Associates
    Lansdale, Pennsylvania 19446, United States
  • Main Street Physicians Care Waterway
    Little River, South Carolina 29566, United States
  • OnSite Clinical Solutions, LLC
    Rock Hill, South Carolina 29732, United States
  • Monument Health Clinical Research
    Rapid City, South Dakota 57701, United States
  • Health Concepts
    Rapid City, South Dakota 57702, United States
  • The Jackson Clinic
    Jackson, Tennessee 38301, United States
  • Affinity Health Corp.
    Nashville, Tennessee 37203, United States
  • Tennessee Center for Clinical Trials
    Tullahoma, Tennessee 37388, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Juno Research, LLC
    Houston, Texas 77040, United States
  • Texas Institute of Cardiology
    McKinney, Texas 75071, United States
  • Southern Endocrinology Associates
    Mesquite, Texas 75149, United States
  • FMC Science
    Round Rock, Texas 78681, United States
  • Carient Heart & Vascular
    Manassas, Virginia 20109, United States
  • Manassas Clinical Research Center
    Manassas, Virginia 20110, United States
  • Charleston Area Medical Center (CAMC) Clinical Trials Center
    Charleston, West Virginia 25304, United States
  • MHAT Sv. Ivan Rilski - 2003 OOD
    Dupnitsa, 2600, Bulgaria
  • University Multiprofile Hospital for Active Treatment Pulmed OOD
    Plovdiv, 4000, Bulgaria
  • SHATC Medica Cor EAD
    Rousse, 7013, Bulgaria
  • Medical Center for Specialized Medical Help in Cardiovascular Diseases OOD
    Sofia, 1000, Bulgaria
  • MBAL National Cardiology Hospital
    Sofia, 1309, Bulgaria
  • University Multiprofile Hospital for Active Treatment Alexandrovska
    Sofia, 1431, Bulgaria
  • University Multiprofile Hospital for Active Treatment
    Sofia, 1431, Bulgaria
  • Medico Dental Center ISUL Tsaritsa Yoanna EOOD
    Sofia, 1527, Bulgaria
  • UMHAT Prof. Dr. Stoyan Kirkovich
    Stara Zagora, 6003, Bulgaria
  • Diagnostic Consultative Center Equita (DCC Equita)
    Varna, 9000, Bulgaria
  • Specialized Hospital for Active Treatment of Cardiology
    Varna, 9020, Bulgaria
  • ARC Biosystems
    Vancouver, British Columbia V6Z 2C7, Canada
  • Centricity Research - Vaughan Endocrinology
    Concord, Ontario L4K 4M2, Canada
  • Centricity Research - Etobicoke Endocrinology
    Etobicoke, Ontario M9R 4E1, Canada
  • Centricity Research - Oshawa Multispecialty
    Oshawa, Ontario L1J 2K9, Canada
  • Bluewater Clinical Research Group Inc
    Sarnia, Ontario N7t 4X3, Canada
  • Centricity Research - Toronto LMC Multispecialty
    Toronto, Ontario M4G 3E8, Canada
  • Ecogene-21
    Chicoutimi, Quebec G7H 7K9, Canada
  • Montreal Heart Institute - Institut de Cardiologie de Montreal
    Montreal, Quebec H1T 1C8, Canada
  • Institute de Recherches Cliniques de Montreal
    Montreal, Quebec H2W 1R7, Canada
  • Clinique des Maladies Lipidiques de Quebec Inc.
    Québec, Quebec G1V 4W2, Canada
  • Centricity Research - Barrie Endocrinology
    Barrie, L4N 7L3, Canada
  • Centricity Research - Brampton Endocrinology
    Brampton, L6S 6J6, Canada
  • Centre de Recherche Saint-Louis
    Québec, G1W 4R4, Canada
  • UNIVMED s.r.o. - Kardiologicka Ambulance
    Brno, 60300, Czechia
  • Cevni ambulance - MATMED s.r.o.
    Hodonín, 695 01, Czechia
  • Edumed s.r.o., Kardiologicka, endokrinologicka, diabetologicka a interni ambulance Nachod
    Jaroměř, 551 01, Czechia
  • Affidea Praha s.r.o.
    Prague, 148 00, Czechia
  • Diabetologicka a endokrinologicka ambulance Milan Kvapil s.r.o
    Prague, 149 00, Czechia
  • Endokrinologie Cerny Most s.r.o.
    Prague, 19800, Czechia
  • AeskuLab k.s
    Teplice, 415 01, Czechia
  • MUDr. Nina Zemkova s.r.o. Interni Ambulance
    Uherské Hradiště, 686 68, Czechia

Showing the first 100 of 168 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Marston NA, Bergmark BA, Prohaska TA, Moura FA, Zimerman A, Alexander VJ, Kang YM, Weinland J, Ran X, Murphy SA, Zhang S, Li D, Banach M, Stroes ESG, Kiss R, Gaudet D, Vrablik M, Goudev A, Bax JJ, Budoff MJ, Foldyna B, Lu MT, Tsimikas S, Giugliano RP, Sabatine MS. Effect of APOC3 Inhibition With Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study. Circulation. 2026 May 19;153(20):1539-1548. doi: 10.1161/CIRCULATIONAHA.126.080012. Epub 2026 Mar 30. PubMed 41910513 ↗
  • Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA, Kang YM, Weinland J, Murphy SA, Goodrich EL, Zhang S, Li D, Banach M, Stroes E, Lu MT, Tsimikas S, Giugliano RP, Sabatine MS; Essence-TIMI 73b Investigators. Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. N Engl J Med. 2025 Oct 2;393(13):1279-1291. doi: 10.1056/NEJMoa2507227. Epub 2025 Aug 30. PubMed 40888739 ↗
  • Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA, Kang YM, Murphy SA, Zhang S, Lu MT, Karwatowska-Prokopczuk E, Tsimikas S, Giugliano RP, Sabatine MS. Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk: Rationale and design of the Essence-TIMI 73b trial. Am Heart J. 2025 Aug;286:116-124. doi: 10.1016/j.ahj.2025.02.022. Epub 2025 Mar 11. PubMed 40081744 ↗

Individual participant data

Plan to share: Yes — Ionis may share anonymized individual participant data, aggregated clinical data, and other types of data that support the results in this study. Data requests from qualified researchers will be considered once all three of the following criteria are met: (1) 12 months from marketing approval of the study drug in both the United States and European Union; (2) 18 months from conclusion of the study; and (3) 6 months from publication of study article. Access would be via a secure environment and is contingent upon approval of a research proposal and entry into an appropriate data use agreement. Requests to access data can be submitted via the website https://vivli.org/ourmember/ionis/.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Aug 2024, 20 months.

Of 28 industry-sponsored phase 3 interventional studies under Hypertriglyceridemia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 31. This study's 20 months is below that.

Counting every sponsor, half of 29 studies reached it within 24 months; a quarter within 18 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2022
First posted
Nov 9, 2022
StartActual
Nov 21, 2022
Primary completionActual
Aug 8, 2024
CompletionActual
Jun 9, 2025
Results delay requested
Jul 9, 2025
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05610280
Responsible party
Sponsor
First posted
Nov 9, 2022
Start date
Nov 21, 2022
Primary completion
Aug 8, 2024
Completion
Jun 9, 2025
Last update
Feb 10, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olezarsen

Start the discussion